POCML 4 Inc. Files Filing Statement in Connection With Proposed Qualifying Transaction With MediPharm Labs Inc.; Expects to Commence Trading on TSXV Under the Ticker Symbol “LABS” on or About October 3, 2018
TORONTO, Sept. 25, 2018 (GLOBE NEWSWIRE) — POCML 4 Inc. (TSXV: POCM) (the “Company”) is pleased to announce that it has filed on SEDAR its filing statement dated effective September 24, 2018 (the “Filing Statement”) in connection with its proposed business combination with MediPharm Labs Inc. (“MediPharm”), which will result in a reverse take-over of the Company by the shareholders of MediPharm (the “Transaction”). Subject to satisfaction of all conditions and approvals, including the satisfaction of the conditions of the TSX Venture Exchange (the “TSXV”), the Transaction is expected to close on or about October 1, 2018. The Company expects that the common shares of the Company as they exist after closing of the Transaction will commence trading on the TSXV under the symbol LABS on October 3, 2018.
For further information, please refer to the Filing Statement on SEDAR at www.sedar.com, as well as the press releases of the Company dated May 15, May 31, June 29, July 16, August 23, 2018 and September 21, 2018 available on SEDAR at www.sedar.com.
About MediPharm Labs Inc.
Founded in 2015, MediPharm is a pioneer in the cannabis industry and has the distinction of being the first company in Canada to become a licensed producer for cannabis oil production under the Access to Cannabis for Medical Purposes Regulations (ACMPR) without first receiving a cannabis cultivation licence. This expert focus on cannabis concentrates from our cGMP (current Good Manufacturing Practices) and ISO standard clean rooms and critical environments laboratory, allows MediPharm to work with its established, Health Canada-approved cultivation partners to produce pharmaceutical-grade cannabis oil with a competitive advantage. MediPharm is research-driven and focused on downstream secondary extraction methodology, distillation, and cannabinoid isolation and purification. MediPharm provides B2B contract processing of cannabis to Canadian authorized licensed producers and appropriate international growers, supplying integrity-assured cannabis oil to qualified companies for sale under their own brand. In addition, MediPharm will supply raw materials, formulations, processing and packaging for the creation of ready-to-sell advanced derivative products.
Website: www.medipharmlabs.com
